Holly Hagan

Professor Emeritus

Professional overview

Dr. Holly Hagan is Professor Emeritus at the School of Global Public Health. Trained as an infectious disease epidemiologist, Dr. Hagan’s work has sought to understand the causes and consequences of substance use disorders.  Her research has examined blood-borne and sexually-transmitted infections among people who use drugs. She is an internationally-recognized expert in the etiology, epidemiology, natural history, prevention and treatment of hepatitis C virus infection among PWUD, and in 2014 her work was recognized by the US Department of Health and Human Services with the President’s Award for Leadership in the Control of Viral Hepatitis in the United States. Dr. Hagan served on the Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis in the United States, and she has been an advisor to the US Department of Health and Human Services, the CDC, and the Canadian Institutes of Health on national programs to detect, diagnose and treat HCV infections. She was recently appointed to the National Academy of Medicine Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs.

Dr. Hagan is the Director of the NIDA P30 Center for Drug Use and HIV|HCV Research at Global Public Health, which provides research support to investigators throughout NYU and in two other NYC institutions. In 2017, she was selected by NIDA to chair the Executive Steering Committee for the Rural Opioid Initiative funded by NIH, CDC, SAMHSA and the Appalachian Regional Commission. Her research has shifted to examining the impact of the opioid crisis more broadly, to include studying the epidemiology of fatal and non-fatal overdose among PWUD. She was chosen by the American Foundation for AIDS Research to be the Principal Investigator for the New York State Opioid Prevention Center pilot study, which will examine the safety and effectiveness of the Supervised Consumption Sites to be implemented in New York City and in upstate NY. 

Education

PhD Epidemiology, University of Washington, Seattle, WA

MPH Epidemiology, University of Massachusetts, Amherst, MA

BA Russian Studies, Evergreen State College, Olympia, WA

Publications

Publications

Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities

Correspondence : Reply to gyarmathy

Evaluating Respondent-Driven Sampling in a Major Metropolitan Area : Comparing Injection Drug Users in the 2005 Seattle Area National HIV Behavioral Surveillance System Survey with Participants in the RAVEN and Kiwi Studies

Gender and age patterns in HSV-2 and HIV infection among non-injecting drug users in New York City

Herpes simplex virus type 2 associated with HIV infection among New York heterosexuals living in high-risk areas

Heterosexual HIV and sexual partnerships between injection drug users and noninjection drug users

HIV infection during limited versus combined HIV prevention programs for IDUs in New York City : The importance of transmission behaviors

Reconsidering the internet as an HIV/STD risk for men who have sex with men

Research note : Perspectives on the hierarchy of HIV and hepatitis C disease: Consequences for drug treatment program patients

Syphilis in drug users in low and middle income countries

A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups

Evaluation of a patient referral contact tracing programme for hepatitis B and C virus infection in drug injectors.

Missed opportunities for HIV testing among high-risk heterosexuals

Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs

Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users

Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City

Young adult injection drug users in the United States continue to practice HIV risk behaviors

A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C

Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs

Evaluating Vancouver's supervised injection facility : Data and dollars, symbols and ethics

Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

Improved injection network ascertainment with supplementary elicitation techniques

Meta-regression of hepatitis c virus infection in relation to time since onset of illicit drug injection : The influence of time and place

Positive deviance control-case life history : A method to develop grounded hypotheses about successful long-term avoidance of infection

The HCV Synthesis Project : Scope, methodology, and preliminary results